Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 1
2023 5
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
HSP70-mediated mitochondrial dynamics and autophagy represent a novel vulnerability in pancreatic cancer.
Ferretti GDS, Quaas CE, Bertolini I, Zuccotti A, Saatci O, Kashatus JA, Sharmin S, Lu DY, Poli ANR, Quesnelle AF, Rodriguez-Blanco J, de Cubas AA, Hobbs GA, Liu Q, O'Bryan JP, Salvino JM, Kashatus DF, Sahin O, Barnoud T. Ferretti GDS, et al. Cell Death Differ. 2024 Jul;31(7):881-896. doi: 10.1038/s41418-024-01310-9. Epub 2024 May 28. Cell Death Differ. 2024. PMID: 38802657 Free PMC article.
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Cetin M, Tokat UM, Gedik ME, Bal H, Sahin OS, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O. Saatci O, et al. bioRxiv [Preprint]. 2023 Nov 5:2023.11.05.565697. doi: 10.1101/2023.11.05.565697. bioRxiv. 2023. Update in: Cell Death Dis. 2024 Jun 15;15(6):418. doi: 10.1038/s41419-024-06814-3 PMID: 38496603 Free PMC article. Updated. Preprint.
Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer.
Gedik ME, Saatci O, Oberholtzer N, Uner M, Akbulut O, Cetin M, Aras M, Ibis K, Caliskan B, Banoglu E, Wiemann S, Uner A, Aksoy S, Mehrotra S, Sahin O. Gedik ME, et al. bioRxiv [Preprint]. 2023 Sep 14:2023.09.12.557273. doi: 10.1101/2023.09.12.557273. bioRxiv. 2023. Update in: Cancer Res. 2024 May 2;84(9):1475-1490. doi: 10.1158/0008-5472.CAN-23-2812 PMID: 37745348 Free PMC article. Updated. Preprint.